EYPT - EyePoint Pharmaceuticals, Inc.
IEX Last Trade
7.27
-0.150 -2.063%
Share volume: 7,994
Last Updated: Fri 27 Dec 2024 05:30:22 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.45%
PREVIOUS CLOSE
CHG
CHG%
$7.42
-0.15
-2.02%
Fundamental analysis
17%
Profitability
0%
Dept financing
23%
Liquidity
75%
Performance
18%
Performance
5 Days
1.10%
1 Month
-18.56%
3 Months
-9.17%
6 Months
-10.50%
1 Year
-68.97%
2 Year
143.52%
Key data
Stock price
$7.27
DAY RANGE
$7.31 - $7.65
52 WEEK RANGE
$7.35 - $30.99
52 WEEK CHANGE
-$68.89
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Nancy S. Lurker
Region: US
Website: eyepointpharma.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: eyepointpharma.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
EyePoint Pharmaceuticals, Inc. provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema. DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the. treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.
Recent news